Intensive Program Extends Lifespan in T2D Patients
Results unequivocally support early, aggressive, and sustained risk factor control in patients with complicated type 2 diabetes.
New Diabetes Drugs May Also Improve Kidney Health
The renal protective effects seen with the SGLT2 inhibitor canogliflizin may be independent of glycemic control, suggest authors of a new post-hoc analysis.
